As of Jun 20
| +2.85 / +5.16%|
The 8 analysts offering 12-month price forecasts for Supernus Pharmaceuticals Inc have a median target of 57.50, with a high estimate of 80.00 and a low estimate of 47.00. The median estimate represents a -0.95% decrease from the last price of 58.05.
The current consensus among 8 polled investment analysts is to Buy stock in Supernus Pharmaceuticals Inc. This rating has held steady since June, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.